Compare Bristol-Myers Squibb Co (BMY) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Global X Lithium & Battery Tech ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.82 (market cap $129.94B), while Global X Lithium & Battery Tech ETF trades at $75.21. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Global X Lithium & Battery Tech ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals.
| BMY | LIT | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $65.89 | $91.62 |
52-Week Low | $42.60 | $44.96 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
LIT trades at $75.60, up 1.15% with a bullish technical signal from moving averages and ADX, though RSI indicates overbought conditions. Recent news highlights strong EV sales growth and lithium demand catalysts, but key financial ratios are unavailable. The stock shows tight support at $74 and resistance at $75.
Outlook is positive due to EV and energy storage momentum, but risks include overbought technicals and reliance on lithium market cycles. Investment opportunity hinges on sustained demand growth, while volatility from commodity prices and competition poses challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
